H. Fisher

发表

Intravesical Chemotherapy for Bladder Tumors

H. Fisher, 1987 .

E‐cadherin cell‐adhesion molecule expression as a diagnostic adjunct in urothelial cytology

J. Ross, C. Sheehan, H. Fisher, 1996, Diagnostic cytopathology.

Telomerase Activity in Human Benign Prostate Tissue and Prostatic Adenocarcinomas

J. Ross, T. Brien, B. Kallakury, 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Rectal ulcer and pseudomalignant epithelial changes after prostate seed brachytherapy: A rare complication with a diagnostic pitfall.

H. Fisher, Hwajeong Lee, T. Jennings, 2018, Annals of diagnostic pathology.

Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma

J. Ross, M. Rifkin, C. Sheehan, 1997, Cancer.

Survivin and Bcl-2 expression in prostatic adenocarcinomas.

J. Ross, C. Sheehan, B. Kallakury, 2009, Archives of pathology & laboratory medicine.

E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome.

J. Ross, H. Fisher, H. Figge, 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.

J. Ross, C. Sheehan, P. Muraca, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era.

B. Mian, H. Fisher, R. Kaufman, 2005, The Journal of urology.

Micropapillary carcinoma: new variant of prostatic acinar adenocarcinoma.

H. Fisher, K. Linos, T. Jennings, 2012, Archives of pathology & laboratory medicine.

Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas.

C. Sheehan, B. Kallakury, H. Fisher, 2005, Human pathology.

Preoperative PDE5i use is a prognostic metric for poor postoperative erectile function in men undergoing radical prostatectomy: An addition to patient counseling

B. Mian, H. Fisher, R. Kaufman, 2016 .

PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.

B. Mian, G. Bratslavsky, H. Fisher, 2008, Urologic oncology.

Relationship of pretreatment transurethral resection of the prostate to survival without distant metastases in patients treated with 125I‐implantation for localized prostatic cancer

W. Whitmore, D. Kaiser, H. Fisher, 1984, Cancer.

Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications.

D. Lamm, S. Brosman, M. Hanna, 1989, Progress in clinical and biological research.

Toxicities of Human Recombinant Interferon-α2 in Patients with Advanced Prostate Carcinoma

H. Fisher, A. Spiers, A. Chang, 1986 .

Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.

J. Figge, B. Kallakury, H. Fisher, 1994, Human pathology.

E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.

C. Sheehan, H. Fisher, H. Figge, 1995, Human pathology.

Expression of Nuclear Factor- (cid:1) B and I (cid:1) B (cid:2) Proteins in Prostatic Adenocarcinomas: Correlation of Nuclear Factor- (cid:1) B Immunoreactivity with Disease Recurrence

C. Sheehan, B. Stringer, B. Kallakury, 2004 .

High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.

D. Trump, H. Lazarus, H. Fisher, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status.

M. Rifkin, H. Fisher, H. Figge, 1995, American journal of clinical pathology.

Verrucous carcinoma of the bladder.

H. Fisher, J. Barada, A. Eastman, 1991, The Journal of urology.

Localized lymphedema (elephantiasis): a case series and review of the literature

David M. Jones, H. Fisher, J. Carlson, 2009, Journal of cutaneous pathology.

Inguinal lymph node metastases from germ cell testicular tumors.

W. Whitmore, P. Sogani, F. Klein, 1984, The Journal of urology.

Prostatic carcinosarcoma: case report and review of literature.

H. Fisher, J. Barada, T. Nazeer, 1991, The Journal of urology.

Prognostic markers inprostate cancer

C. Sheehan, B. Kallakury, H. Fisher, 2002, Expert review of molecular diagnostics.

The prognostic significance of proliferation‐associated nucleolar protein p120 expression in prostate adenocarcinoma

M. Rifkin, C. Sheehan, B. Kallakury, 1999, Cancer.

Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence.

C. Sheehan, B. Stringer, B. Kallakury, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of Nuclear Factor-κB and IκBα Proteins in Prostatic Adenocarcinomas

C. Sheehan, B. Stringer, B. Kallakury, 2004, Clinical Cancer Research.

Prognostic factors in prostate cancer.

C. Sheehan, B. Kallakury, H. Fisher, 2003, American journal of clinical pathology.

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.

C. Sheehan, P. Muraca, H. Fisher, 1997, Human pathology.

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Prabhjot Kaur, C. Sheehan, G. Gray, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tissue-marking scheme for a cost-effective extended prostate biopsy protocol.

B. Mian, H. Fisher, R. Kaufman, 2009, Urologic oncology.

Contribution of HER‐2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis

M. Rifkin, H. Fisher, H. Figge, 1993, Cancer.

Phase I Clinical Study of the Recombinant Oncotoxin TP4O in Superficial Bladder Cancer

Russo, E. Messing, W. Linehan, 2005 .

Prediction of pathologic stage and postprostatectomy disease recurrence by dna ploidy analysis of initial needle biopsy specimens of prostate cancer

M. Rifkin, H. Fisher, H. Figge, 1994, Cancer.

Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas.

C. Sheehan, B. Kallakury, H. Fisher, 2007, Human pathology.

Decreased expression of catenins (α and β), p120 CTN, and E‐cadherin cell adhesion proteins and E‐cadherin gene promoter methylation in prostatic adenocarcinomas

E. Winn-Deen, C. Sheehan, B. Kallakury, 2001 .

Primary peritoneal mullerian adenosarcoma with sarcomatous overgrowth associated with endometriosis: a case report.

H. Fisher, R. Ambros, Ayse D Dincer, 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.

B. Yeap, D. Trump, R. Hahn, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis and Management of Genitourinary Cancer

H. Fisher, 1988 .

Decreased levels of CD44 protein and mRNA in prostate carcinoma: Correlation with tumor grade and ploidy

J. Figge, B. Kallakury, H. Fisher, 1996, Cancer.

Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study)

B. Mian, H. Fisher, R. Kaufman, 2021, Prostate Cancer and Prostatic Diseases.

Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer.

M. Rifkin, C. Sheehan, H. Fisher, 1999, The American journal of surgical pathology.

Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate Cancer

C. Sheehan, B. Kallakury, H. Fisher, 2003, Modern Pathology.

Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas.

E. Winn-Deen, C. Sheehan, H. Fisher, 2001, Cancer.

Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.

S. Parekattil, H. Fisher, B. Kogan, 2003, The Journal of urology.

Expression of Small Non-coding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease.

L. Klotz, A. DiRienzo, B. Mian, 2020, The Journal of urology.

Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate?

H. Thaler, M. Rifkin, H. Fisher, 1996, The Journal of urology.

Role of prostate biopsy schemes in accurate prediction of Gleason scores.

B. Mian, H. Fisher, R. Kaufman, 2006, Urology.

Management of small renal cancers: choices for the patient and physician.

H. Fisher, 2006, The Journal of urology.

DNA ploidy of oncocytic-granular renal cell carcinomas and renal oncocytomas by image analysis.

H. Fisher, J. Barada, O. Solis, 1992, Archives of Pathology & Laboratory Medicine.

Contribution of HER‐2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis

M. Rifkin, H. Fisher, H. Figge, 1993, Cancer.

Management of penile carcinoma: the case for selective application of inguinal lymph node dissection in stages T1-T4.

H. Fisher, 1993, Seminars in urology.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .